Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Freudenstadt – page 23

721 clinical trials in Freudenstadt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Freudenstadt at a glance
721
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

721 trials in Freudenstadt

Open in trial search

Study on Hilar Cholangiocarcinoma Treatment Using Porfimer Sodium and Foscan for Patients with Bile Duct Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:University of Leipzig

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Vinblastine Sulfate
  • Sponsor:GPOH gGmbH

Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Ewing's sarcoma

Recruiting

Study on Ewing Sarcoma Treatment with Vinorelbine and Drug Combination for Patients with Primary and Disseminated Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:GPOH gGmbH

B-cell lymphoma+1

Recruiting

Study of Pembrolizumab for Children with Advanced Melanoma or PD-L1 Positive Solid Tumors and Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of ONC201 for Patients with Newly Diagnosed H3 K27M-mutant Diffuse Glioma After Radiotherapy

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dordaviprone
  • Sponsor:Chimerix Inc.

Gastrectomy

Recruiting

Study on the Effects of Amylase, Protease, and Rizolipase for Patients After Gastrectomy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amylase
  • Sponsor:University of Leipzig

Study of Venetoclax and Decitabine for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study on Durvalumab for Patients with High-Risk Endometrial Cancer After Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Freudenstadt

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical studies focusing on hormone receptor-positive HER2-negative breast cancer, exploring combination therapies with endocrine treatment approaches.

  • Advanced/Metastatic Breast Cancer
  • Hormone Receptor Studies
  • Digital Side Effect Management

Research aims to evaluate treatment effectiveness and patient outcomes through systematic monitoring and assessment.

02 Biliary Tract Cancer Studies

Groundbreaking research investigating advanced biliary tract cancers through combination therapy approaches using immunotherapy and chemotherapy.

  • First-line Treatment Assessment
  • Combination Therapy Safety
  • Multicentre Clinical Evaluation

The research focuses on evaluating novel treatment combinations to improve patient outcomes in advanced disease stages.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.